Linee guida più recenti

Presentazione Revvity – In espansionei confini del potenziale umano attraverso la scienza.
Tutti i prodotti e i servizi precedentemente affiliati a Oxford Immunotec fanno ora parte di Revvity.

Saperne di più

Diversi istituti pubblicano periodicamente linee guida aggiornate sui test per la tubercolosi (TB) per le varie popolazioni. Questa pagina le raccoglie tutte per una maggiore praticità nel reperimento di indicazioni.

Documento dell’Organizzazione Mondiale della Sanità sull’infezione da TB latente: linee guida aggiornate e consolidate per la gestione programmatica 2018

Standard internazionali per la cura della tubercolosi dell’Organizzazione Mondiale della Sanità

Linee guida dei CDC sull’utilizzo dei test IGRA nel quadro della tubercolosi: screening, test e trattamento del personale sanitario statunitense

Linee guida del National Institute for Health and Care Excellence (NICE) sulla tubercolosi NG33

Avviso della Medicines and Healthcare Products Regulatory Agency (MHRA) – Inibitori del fattore di necrosi tumorale alfa e rischio di tubercolosi

Linee guida 2018 della British Society of Rheumatology per la prescrizione e il monitoraggio dei farmaci antireumatici modificanti la malattia (DMARD) non biologici

Standard dello European Centre for Disease Prevention and Control (ECDC) per la cura della tubercolosi nell’Unione europea

Istituto di sanità pubblica francese (Haut Conseil de la Santé Publique). Infezione tubercolare latente. Individuazione, supporto e monitoraggio

Autorità sanitaria francese (Haute Autorité de Santé). Test di rilascio dell’interferone gamma come test di screening in vitro per l’infezione tubercolare latente

Comitato centrale tedesco contro la tubercolosi (Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose)

Riferimenti

Global tuberculosis report 2020. Geneva: World Health Organization; 2020. CC BY-NC-SA 3.0 IGO
Oxford Immunotec. T-SPOT.TB Package Insert – TB-PI-UK-0001 V4
Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American ThoracicSociety/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. Published online December 8, 2016:ciw694. doi:10.1093/cid/ciw694
Wong SH, Gao Q, Tsoi KKF, et al. Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax. 2016;71:64–72.
Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, IGRA Expert Committee, Centers for Disease Control and Prevention (CDC). Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection – United States, 2010. MMWR Recomm Rep. 2010; 59(RR-5:1-25.
WHO End TB Strategy. World Health Organization. Published September 8, 2015. Accessed November 12, 2020.
Wrighton-Smith P, Sneed L, Humphrey F, Tao X, Bernacki E. Screening health care workers with interferon-γ release assay versus tuberculin skin test: Impact on costs and adherence to testing (the SWITCH study). J Occupational & Environmental Med. 2012;54(7):806-815
Oxford Immunotec. T-Cell Xtend Package Insert. PI-TT.610-UK-V6. Abingdon, UK. 2017.
Tuberculosis (TB). Centers for Disease Control and Prevention. CDC Tuberculosis. Published December 31, 2018. Accessed November 12, 2020.
Diabetes Fact Sheets. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/diabetes. Accessed November 12, 2020.
GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology. 2020;5(1):17-30
RA Facts: What are the latest statistics on Rheumatoid Arthritis? Rheumatoid Arthritis Support Network. https://www.rheumatoidarthritis.org/ra/facts-and-statistics/. Accessed November 12, 2020.
The Global HIV/AIDS epidemic. HIV.gov. https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics. Accessed November 12, 2020.
Chronic Kidney Disease (CKD) Symptoms and causes. National Kidney Foundation. https://www.kidney.org/atoz/content/about-chronic-kidney-disease. Accessed November 12, 2020.
TB comorbidities and risk factors. World Health Organization. https://www.who.int/tb/areas-of-work/treatment/risk-factors/en/. Accessed November 12, 2020.
Lai CC, Tan CK, et al. Diagnostic performance of whole-blood interferon-γ assay and enzyme-linked immunospot assay for active tuberculosis. J Microbiol Immunol Infect. 2011 Oct;44(5):406-7. doi: 10.1016/j.jmii.2011.07.002. Epub 2011 Sep 8.
Redelman-Sidi G, Sepkowitz KA. Interferon-gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med 2013; 188:422-431. 2012/12/25. DOI: 10.1164/rccm.201209-1621CI.
US – Take on TB. Centers for Disease Control and Prevention. CDC Take on Tuberculosis Infographic. Accessed January 8, 2020.
Signs & Symptoms. Centers for Disease Control and Prevention. CDC Tuberculosis Signs and Symptoms. Published March 17, 2016. Accessed January 8, 2020.
Exposure to TB. Centers for Disease Control and Prevention. CDC Exposure to TB. Published March 21, 2016. Accessed January 8, 2020.
TB Risk Factors. Centers for Disease Control and Prevention. CDC TB Risk Factors. Published March 18, 2016. Accessed January 8, 2020.
Huebner R, Schein M, Bass J. The tuberculin skin test. Clin Infect Dis. 1993;968-975.
Treatment for TB Disease. Centers for Disease Control and Prevention. CDC Treatment for TB Disease. Published April 5, 2016. Accessed January 8, 2020.